Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis by Phelps, Richard et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Incidence, management, and outcomes of autoimmune
nephropathies following alemtuzumab treatment in patients with
multiple sclerosis
Citation for published version:
Phelps, R, Winston, JA, Wynn, D, Habek, M, Hartung, H-P, Havrdová, EK, Markowitz, GS, Margolin, DH,
Rodriguez, CE, Baker, DP & Coles, AJ 2019, 'Incidence, management, and outcomes of autoimmune
nephropathies following alemtuzumab treatment in patients with multiple sclerosis', Multiple Sclerosis
Journal, pp. 1352458519841829. https://doi.org/10.1177/1352458519841829
Digital Object Identifier (DOI):
10.1177/1352458519841829
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Multiple Sclerosis Journal
Publisher Rights Statement:
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License
(http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and
distribution of the work without further permission provided the original work is attributed as specified on the
SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
https://doi.org/10.1177/1352458519841829
https://doi.org/10.1177/1352458519841829
MULTIPLE
SCLEROSIS MSJ
JOURNAL
journals.sagepub.com/home/msj 1
Multiple Sclerosis Journal
 1 –16
DOI: 10.1177/ 
1352458519841829
© The Author(s), 2019.
Article reuse guidelines:  
sagepub.com/journals-
permissions
Introduction
Anti-glomerular basement membrane (anti-GBM) 
disease following alemtuzumab therapy in multiple 
sclerosis (MS) patients was first reported in 2006.1 
Subsequently, there has been intense renal surveil-
lance during clinical trial2–6 and non-trial treatments.
Although drug-related nephropathies are well 
described with several mechanisms recognized,7 
alemtuzumab-related nephropathies occur in the con-
text of an increased risk of various de novo autoimmune 
disorders following alemtuzumab treatment for MS, 
most commonly thyroid autoimmune conditions (5-year 
incidences: all thyroid disorders 40%–45%; serious thy-
roid adverse events 4%–5%)8,9 and immune thrombo-
cytopenia (1%–3%).8–10
Alemtuzumab was initially approved (Campath®/
MabCampath®) for treatment of B-cell chronic lym-
phocytic leukemia;11 it has also been used in off-label 
applications, including MS (prior to approval for this 
indication),1 refractory vasculitis,12 solid organ 
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Background: Autoimmune disorders including nephropathies have been reported more frequently in 
alemtuzumab-treated multiple sclerosis (MS) patients than in the general population.
Objective: Describe instances of autoimmune nephropathy in alemtuzumab-treated MS patients.
Methods: Cases were identified from safety monitoring within the alemtuzumab relapsing-remitting 
multiple sclerosis (RRMS) clinical development program (CDP) or post-marketing, or following off-
label use.
Results: As of 16 June 2017, 16 autoimmune nephropathies have occurred following alemtuzumab treat-
ment for MS. The incidence of autoimmune nephropathies was 0.34% within the CDP (5/1485 patients). 
The five CDP cases (one of anti-glomerular basement membrane (anti-GBM) disease, two of membra-
nous glomerulonephropathy, and two of serum anti-GBM antibody without typical anti-GBM disease) 
were identified early, responded to conventional therapy (where needed), and had favorable outcomes. 
Three of 11 cases outside the CDP occurred following off-label alemtuzumab use prior to approval for 
RRMS and were all anti-GBM disease. Diagnosis was delayed in one of these three cases and another did 
not receive appropriate treatment; all three cases resulted in end-stage renal failure. All anti-GBM disease 
cases with documented urinalysis demonstrated prior microscopic hematuria.
Conclusion: Close monitoring of alemtuzumab-treated MS patients facilitates diagnosis and treatment 
early in the nephropathy course when preservation of renal function is more likely.
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transplantation,13 and as a conditioning regimen for 
hematopoietic stem cell transplantation.14 Alemtuzumab 
(LEMTRADA®) has been approved in more than 70 
countries for use in adults with relapsing forms of MS, 
including countries of the European Union for patients 
with active relapsing-remitting multiple sclerosis 
(RRMS) defined by clinical and imaging features, and 
in the US for patients who generally have had an inad-
equate response to two or more prior therapies.15,16 For 
RRMS, alemtuzumab is dosed as two initial treatment 
courses at baseline and 12 months later, and additional 
courses (up to two in Europe; no limit in the United 
States) as needed, administered ⩾12 months after the 
previous dose.15,16 The drug is detectable in serum for 
~30 days after administration.15
De novo autoimmunity may relate to the proposed 
mechanism of action of alemtuzumab. This human-
ized monoclonal antibody targets B and T lympho-
cytes (both CD4+ and CD8+ T cells) for depletion,17,18 
followed by a distinctive pattern of B- and T-cell 
repopulation. B cells return to baseline levels within 
approximately 6 months; T cells recover more slowly, 
with levels generally reaching lower limits of normal 
by 12 months.19 Relative increases in memory and 
regulatory T-cell levels occur during immune recon-
stitution, resulting in a shift from pro- to anti-inflam-
matory cytokine profiles.20 Decreases in circulating 
B and T cells and their altered behavior upon subse-
quent repopulation may explain the efficacy of alem-
tuzumab in reducing the risk of relapses, delaying 
disease progression, and providing efficacy in the 
absence of continuous treatment.19,21,22 Additional 
mechanistic studies are required to establish this 
hypothesis.
Clinical trials have established alemtuzumab as a 
highly efficacious disease-modifying therapy in 
patients with active RRMS.2–4 Effects on disease 
activity include improvements in relapse and disabil-
ity outcomes, reduction in the occurrence of new 
brain magnetic resonance imaging (MRI) lesions, and 
reduction of brain volume loss to levels similar to 
those in people without MS.8,9,23–27
The purpose of this article is to review the cases of de 
novo renal autoimmunity in MS patients treated with 
alemtuzumab within or outside of the clinical devel-
opment program (CDP) to better understand their 
natural history, and to assess implications for moni-
toring and treatment.
Patients and methods
Cases of autoimmune nephropathy arising in alemtu-
zumab-treated MS patients are reported as of 16 June 
2017. Cases occurring within the CDP were identified 
under a safety monitoring program run by the 
manufacturer that included renal monitoring 
(Table 1). Nephropathy cases are described alpha-
betically based on overall chronology (Figure 1). 
Five cases occurred within the CDP (patients 
C–F and J), comprising the phase 2 CAMMS223 
(NCT00050778) trial,2 phase 3 CARE-MS I 
(NCT00530348) and CARE-MS II (NCT00548405) 
trials,3,4 4-year open-label CAMMS03409 extension 
Table 1. Summary of routine renal safety monitoring within the alemtuzumab CDP and post-marketing.
Renal monitoring within the CDP
 • Monitoring of renal function in CAMMS223 initially included quarterly serum creatinine testing2
 • Following the detection of anti-GBM disease in patient C in CAMMS223, renal monitoring for all trials was 
enhanced to include the following:6,10
- Monthly evaluation of serum creatinine levels and urinalysis with microscopy in all study patients who 
received alemtuzumab
- Intensified surveillance in any patient with abnormal renal results, with criteria for urgent or non-urgent referral 
to a nephrologist
- Education for investigators and patients about anti-GBM disease
- Monthly patient questionnaires that queried for the presence of hematuria, offset by 2 weeks from laboratory 
collections
Renal monitoring post-marketing
 • Risk Evaluation and Mitigation Strategy in the United States and Risk Management Plan in the European Union 
and other regions, including healthcare professional and patient education15,28
 • Alemtuzumab labeling recommends (a requirement in the United States) that serum creatinine levels and urinalysis 
with cell counts are obtained prior to initiation of treatment and at monthly intervals thereafter until 48 months 
after the last infusion15,16
CDP: clinical development program; GBM: glomerular basement membrane.
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study (NCT00930553),8,9 and ongoing TOPAZ exten-
sion study (NCT02255656).29 Patients provided written 
informed consent for the analyses described in this study. 
Surveillance in these trials included measurements of 
serum creatinine, urine dipstick tests for proteinuria and 
hematuria, and urine microscopy (monitoring frequency 
was initially quarterly, but increased to monthly after the 
first CDP case (patient C) was reported). Additional 
nephropathy cases have occurred post-marketing, and 
outside of either the CDP or post-marketing setting 
(patients A, B, and G) following off-label use of alemtu-
zumab (Campath®/MabCampath®). A Medline search 
revealed no additional reported cases.
Details of each case were obtained from MedWatch 
reports and the treating physicians. When available, 
these included clinical histories, laboratory analyses, 
and pathology data. Anti-GBM disease cases were 
classified as those in which a renal biopsy demon-
strated crescentic glomerulonephritis with linear depo-
sition of immunoglobulin G (IgG), or there was severe 
nephritis without interpretable immunofluorescence 
imaging, but high levels of circulating anti-GBM anti-
bodies. Biopsies from patients C, E, and F were avail-
able for review by a renal pathologist (G.S.M.). The 
status of patients’ MS was also evaluated for cases 
occurring in the CDP.
Results
Sixteen cases of autoimmune nephropathy have been 
reported. The first two occurred in an investigator-
sponsored pilot study in MS patients1 before com-
mencement of the alemtuzumab CDP in RRMS. Five 
cases occurred within the CDP, and one case occurred 
during independent, physician off-label use of alem-
tuzumab before its approval for RRMS. Eight further 
cases have been reported post-marketing. The CDP 
and post-marketing settings included close monitor-
ing of renal function as part of the trial protocols6 and 
Risk Management Plan/Risk Evaluation and Mitigation 
Strategy,15,28 respectively (Table 1). All cases of auto-
immune nephropathy in MS patients treated with 
alemtuzumab occurred (where known) in patients 
Figure 1. Cases of nephropathy associated with alemtuzumab treatment in MS patients. The nephropathy cases are 
shown chronologically based on date of diagnosis, and divided according to disease type (anti-GBM disease, anti-GBM 
antibodies, MGN, and nephritis) and renal outcome. The five cases occurring within the CDP resolved with normal 
renal function (patients C–F and J). The three cases of anti-GBM disease occurring during off-label use (patients A, B, 
and G) resulted in end-stage renal disease (ESRD; highlighted in orange). The eight post-marketing cases (patients H, I, 
and K–P) require further follow-up to determine outcomes; four of these eight cases (patients H, I, K, and O) involved 
possible immunological renal disease where full information could not be obtained; patients I and O had probable anti-
GBM disease, but insufficient information was available to confirm this diagnosis. Patient A (index case) was diagnosed 
in April 2003 and reported in 2006.1 Dates of diagnosis for the other cases were: patient B, March 2005; patient C, 
September 2008; patient D, October 2010; patient E, January 2011; patient F, April 2012; patient G, July 2012; patient H, 
July 2014; patient I, during 2015; patient J, August 2015; patient K, September 2016; patient L, December 2016; patient 
M, March 2017; patient N, April 2017; patient O, date unknown (reported May 2017); patient P, date unknown (reported 
June 2017).
CDP: clinical development program; GBM: glomerular basement membrane; MGN: membranous glomerulonephropathy.
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aged 25–58 years, and with onset within 39 months of 
the last alemtuzumab administration in all but one 
patient. The exception was a male patient who, 
60 months after treatment, developed a transitory and 
self-remitting elevation in serum creatinine with 
detectable serum anti-GBM antibodies, possibly in 
relation to a mild infectious illness (patient J).
The incidence of autoimmune nephropathies (includ-
ing anti-GBM disease) with alemtuzumab within the 
CDP was 0.34%, with a total of 1485 patients at risk 
and 8632 patient-years of follow-up (median follow-
up 6.1 years (range, 0.7–12.7 years)). Through 16 June 
2017, approximately 15,000 patients were treated 
worldwide for MS with alemtuzumab (LEMTRADA®). 
Based on the nephropathy cases reported so far, this 
corresponds to an estimated, point in time, post- 
marketing frequency rate of approximately 0.05%.
Anti-GBM disease cases
Seven patients developed anti-GBM disease, veri-
fied in most cases by biopsy showing the presence 
of crescentic glomerulonephritis and linear deposi-
tion of immunoglobulin along the GBM (Table 2). 
Two of these (patients A (index case) and B) were 
treated with alemtuzumab at doses higher than those 
currently approved for treatment of RRMS and with 
a different treatment regimen. Six cases exhibited 
rapid loss of renal function between 9 and 39 months 
after last receiving alemtuzumab (time to event 
onset not available for patient P). In five cases, there 
was a period of at least 1 month during which hema-
turia and/or elevated serum creatinine was detected 
before accelerating loss of renal function (pre-onset 
urinalysis not available for patients A, N, and P).
Anti-GBM antibodies were detected at the time of rec-
ognition of acute kidney failure in 6 patients (patient C 
tested negative). Analysis of serum taken before rec-
ognition of acute kidney failure revealed that patient A 
had no detectable serum anti-GBM antibodies 1 month 
prior.1 Patient G had detectable anti-GBM antibodies 
and microscopic hematuria when serum creatinine 
was still normal. HLA genotyping data were only 
available for patient A, who was found to carry a HLA 
DRB1*15 allele.30 Alleles of the major histocompati-
bility complex defined as HLA DRB1*15 are associ-
ated with an increased risk for anti-GBM disease and 
MS.31,32 Kidney biopsy data available for 5 patients 
revealed crescentic glomerulonephritis with linear IgG 
deposition (where measured) consistent with anti-
GBM disease, including the single case (patient C) 
with histopathology images available for review 
(Figure 4(a) and (b)). The percentage of glomeruli 
with crescents ranged from 15%–98% (Table 2).
All 7 patients received conventional treatment, typically 
with combinations of plasmapheresis, dialysis, cyclo-
phosphamide, and steroids; however, there was varia-
tion in the regimens employed and timing of therapy in 
relation to the onset of renal failure. Patients A and B 
developed disease outside of a close monitoring pro-
gram. Despite being diagnosed and treated (including 
plasmapheresis and steroids) within 3 days of first 
symptoms, and within the month after diagnosis, 
respectively, neither patient recovered renal function; 
however, both survived and underwent successful renal 
transplantation without recurrence of anti-GBM dis-
ease. Patient C was diagnosed through the CDP moni-
toring program and was treated with plasmapheresis, 
cyclophosphamide, and steroids within 6 weeks of first 
signs of elevated serum creatinine (Figure 2); the patient 
recovered and retained independent near-normal renal 
function. Patient G was treated within 2 months of first 
symptoms of hematuria when she had intact renal func-
tion and only 15% crescents on renal biopsy. The patient 
was treated solely with plasmapheresis (she declined 
cyclophosphamide), and withdrew from plasmaphere-
sis for 1 week due to personal reasons approximately 
1 month after diagnosis. She subsequently experienced 
a rapid deterioration in renal function. Full conventional 
treatment with plasmapheresis, cyclophosphamide, and 
steroids was introduced when renal failure was 
advanced (serum creatinine 530 µmol/L (6 mg/dL)). 
After 6 months on dialysis and disappearance of circu-
lating anti-GBM autoantibodies, the patient underwent 
successful renal transplantation without recurrence of 
anti-GBM disease. All 3 post-marketing cases (patients 
M, N, and P) were dialysis-dependent at most recent 
follow-up based on the information available.
Cases in which anti-GBM antibodies occurred 
without typical anti-GBM disease
Three cases are reported in which anti-GBM antibodies 
were detected without classical anti-GBM disease 
(Table 3). Patient D presented as nephrotic syndrome 
with normal glomerular filtration rate (GFR), but the 
patient’s serum contained a very low titer (just above 
the laboratory’s reference range) of anti-GBM antibod-
ies. The renal biopsy was reported as membranous 
nephropathy, but subsequent small rises in serum anti-
GBM antibody titer prompted initiation of plasmapher-
esis, cyclophosphamide, and steroids, resulting in 
remission of nephrosis and disappearance of anti-GBM 
antibodies. At 39 months after last treatment for 
nephropathy, the patient was in remission requiring no 
medication, anti-GBM antibodies were not detectable, 
serum creatinine was within the normal range (Figure 
2), and there was no detectable proteinuria (Figure 3). 
Patient J developed a transitory serum anti-GBM anti-
body titer in the context of a brief self-limiting disease, 
R Phelps, JA Winston et al.
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and patient L was diagnosed with pauci-immune vas-
culitis and managed accordingly.
Membranous glomerulonephropathy cases
Two cases (patients E and F) presented with 
nephrotic syndrome and normal serum creatinine 5 
and 13 months after alemtuzumab treatment, 
respectively; both were diagnosed through the 
monitoring program established for the CDP. In 
both patients, renal biopsy revealed membranous 
glomerulonephropathy (MGN), stage 1, which was 
confirmed on review (Table 4 and Figure 4). 
Immunofluorescence staining in both biopsies was 
positive for IgG, complement component 3, and 
kappa and lambda light chains, and electron micros-
copy revealed global small subepithelial electron 
dense deposits, without significant intervening 
GBM spikes. In patient E, mesangial electron dense 
deposits were also noted. In patient F, who was 
considerably older than patient E, MGN was super-
imposed on changes of subcapsular scarring, arte-
rionephrosclerosis, and focal renal atheroemboli.
Both patients were treated with angiotensin-converting 
enzyme inhibitors and diuretics. Patient E was in spon-
taneous remission 45 months after diagnosis (62 months 
after initiating alemtuzumab treatment) and, at most 
recent follow-up (67 months after diagnosis), her GFR 
was normal with minimal proteinuria (Figure 3). 
Patient F was in complete remission at last follow-up 
(21 months following diagnosis) with no detectable 
proteinuria (Figure 3). Both patients had serum creati-
nine levels within normal range (Figure 2).
Cases of possible immunological renal disease 
when full information could not be obtained
In addition to the nephropathy cases mentioned above, 
four further cases (patients H, I, K, and O) have been 
reported to the sponsor in the post-marketing setting 
(Table 5); however, they cannot be independently 
Figure 2. Serum creatinine over time for nephropathy cases occurring during the CDP. Black arrows indicate 
alemtuzumab treatment courses. Horizontal dashed line indicates upper limit of normal established in each testing 
laboratory using differently calibrated control levels. Months shown are from first alemtuzumab treatment. Scale of 
horizontal axes varies due to differing timing of treatment and event onset in each patient. Patient F received subcutaneous 
interferon beta-1a (44 µg 3× weekly) in the CAMMS223 trial (Month 0 to Month 36) before receiving alemtuzumab.
CDP: clinical development program.
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confirmed due to limitations of pharmacovigilance 
data collection. These include a case of focal segmen-
tal glomerulonephritis with proteinuria (patient H) 
and two cases of severe nephritis treated as anti-GBM 
disease (patients I and O). Information on renal out-
comes is unavailable in all four cases and further fol-
low-up is awaited.
MS status of patients within the CDP
Evaluation of the MS status of the five cases (patients 
C‒F and J) occurring within the CDP suggested that 
the onset of nephropathy was not associated with 
exacerbation of MS. Patients C and E experienced a 
2-point increase in Expanded Disability Status Scale 
(EDSS) score from core study baseline to most recent 
visit, and annualized relapse rate (ARR) remained 
low (Table 6). Patients D and J showed a decreased 
EDSS score from baseline to most recent visit and did 
not relapse over the same period. Patient F experi-
enced an increased EDSS score from 3.5 at baseline 
to 6.0 at most recent visit and a relatively high ARR 
(0.45) at most recent visit; however, the patient’s 
EDSS score was already 6.0 over a 5-month period 
before the nephropathy event.
Discussion
The observation of up to 16 cases of de novo renal 
autoimmunity to date in MS patients treated with 
alemtuzumab suggests an elevated relative risk for 
nephropathies. The overall incidence of nephropa-
thies as of 16 June 2017 was 0.34% within the alem-
tuzumab CDP for RRMS, but so far a lower (0.05%) 
incidence has been observed in the post-marketing 
setting. Post-marketing event frequencies are not 
directly comparable with clinical trial incidences 
because of differences in ascertainment methodology 
and follow-up duration, and the limitations of post-
marketing reporting, including possible under-report-
ing, limited availability of clinical details, and 
potential for inaccurate diagnoses.33 A case of anti-
GBM disease was also previously reported in a patient 
who received off-label alemtuzumab treatment for 
systemic vasculitis.1
Anti-GBM disease occurs rarely in the normal popu-
lation (up to 1 case/million people/year), with a slight 
male predominance.34 It has been reported in MS 
patients35 and, although the available data do not ena-
ble estimation of the incidence rate, it may be slightly 
higher than in the normal population, as MS patients 
have an increased risk for other autoimmune dis-
eases.36 MS and anti-GBM disease are associated 
with inheritance of the same HLA class II allele, HLA 
Figure 3. Urine protein (dipstick test) over time for 
nephropathy cases occurring during the CDP. Urine 
protein was not available for patient C (routine monitoring 
was modified to include urinalysis following this case). 
Black arrows indicate alemtuzumab treatment courses. 
Numbering on vertical axes refers to number of pluses 
from dipstick score. Months shown are from first 
alemtuzumab treatment. Scale of horizontal axes varies 
due to differing timing of treatment and event onset in each 
patient. Patient F received subcutaneous interferon beta-1a 
(44 µg 3× weekly) in the CAMMS223 trial (Month 0 to 
Month 36) before receiving alemtuzumab.
CDP: clinical development program.
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DRB1*15:01.31,32 In MS, the association with this 
allele has been reported to be female-specific,37 and it 
is interesting to note that the majority of cases of anti-
GBM disease following alemtuzumab treatment to 
date have occurred in female patients, with one patient 
(patient A) a confirmed carrier of HLA DRB1*15.30
MGN is a common etiology of nephrotic syndrome in 
adults, with an incidence in the normal population of 
4–10 cases/million people/year.38 MGN may be idio-
pathic and associated with phospholipase A2 receptor 
autoantibodies, or may occur secondary to other dis-
eases such as systemic lupus erythematosus or hepati-
tis B and C infections.39 Like anti-GBM disease, very 
few cases of MGN have been reported in MS patients.40
Mechanisms underlying the increased risk of autoim-
mune-mediated conditions with alemtuzumab are not 
Figure 4. Renal biopsy findings. (a) Patient C: by light microscopy, a glomerulus exhibits a segmental cellular crescent 
(yellow arrow), characteristic of anti-GBM disease (trichrome, 400× magnification). (b) Patient C: immunofluorescence 
reveals linear staining of the GBM for IgG, diagnostic of anti-GBM disease (300× magnification). (c) Patient E: by light 
microscopy, a glomerulus appears unremarkable in this patient with stage 1 MGN (400× magnification). (d) Patient 
E: immunofluorescence reveals granular global staining of the GBM (300× magnification). (e) Patient E: electron 
microscopy reveals global small subepithelial electron dense deposits, without significant intervening GBM spikes, 
diagnostic of stage 1 MGN (5000× magnification). (f) Patient F: similar to patient E, stage 1 changes of MGN are seen 
on ultrastructural evaluation of the biopsy on patient F (5000× magnification). GBM: glomerular basement membrane; 
MGN: membranous glomerulonephropathy.
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fully understood. However, homeostatic expansion of 
lymphocytes may be linked to lymphopenia-associ-
ated autoimmunity41,42 and represents a potential 
explanation for increased nephropathy risk in alemtu-
zumab-treated patients.
Evaluation of the MS status of five autoimmune 
nephropathy cases occurring within the CDP sug-
gested that nephropathy onset was not associated with 
exacerbation of MS. Although based on a small num-
ber of patients, this finding is consistent with a study 
showing that another autoimmune disorder, thyroid 
dysfunction, did not adversely affect MS outcomes in 
alemtuzumab-treated patients.43
A number of preliminary conclusions may be drawn 
regarding the nature of the risk of renal disease with 
alemtuzumab and the potential for its mitigation. 
First, with regard to the natural history of anti-GBM 
disease, five of the seven patients with the disease 
exhibited a prodrome of at least a month with indica-
tions of renal disease in the form of microscopic 
hematuria and/or elevated serum creatinine, detected 
while asymptomatic by renal surveillance laboratory 
testing. Idiopathic anti-GBM disease is usually 
viewed as fulminant, as it was in the other two alem-
tuzumab cases, but an asymptomatic prodrome could 
easily be missed in clinical practice. There have been 
reports of idiopathic anti-GBM cases with such a pro-
dromal period, notably in patients also presenting 
with lung hemorrhage and/or hemoptysis and hematu-
ria.44 Although it is possible that a prodrome is a dis-
tinctive feature of anti-GBM disease related to 
alemtuzumab treatment for MS, more likely, anti-
GBM disease (with or without lung involvement) 
should be reconceived as a condition that takes at 
least a few weeks to build through minor renal injury 
to the well-described fulminant presentation.
Second, at least in the alemtuzumab group, serum 
anti-GBM antibodies were not always detectable by 
conventional assays during the prodrome and hence 
cannot be used reliably to rule out a diagnosis of anti-
GBM disease. Of particular note, in three of the 
reported nephropathy cases, serum anti-GBM anti-
bodies were detected without classical anti-GBM dis-
ease. False-positives may occur due to non-specific 
binding in patients with inflammatory diseases.44 
However, two of these three cases occurred in the 
presence of MGN and pauci-immune vasculitis, 
respectively, which is consistent with previous reports 
of anti-GBM antibodies occurring in combination 
with these diseases.34
Third, outcomes and response to treatment are not 
obviously different from those in patients with these 
conditions occurring outside the context of alemtu-
zumab treatment. In particular, conventional treatment 
of anti-GBM disease in alemtuzumab-treated patients 
was effective when started before substantial renal 
damage had occurred (patient C, within the CDP with 
close monitoring), and failed to preserve native renal 
function when treatment was interrupted (patient G) or 
when renal injury was very advanced (patients A, B, 
N, and P, all of whom were reported to have severe 
injury on biopsy with >90% glomerular crescents).
Finally, close observation of alemtuzumab patients 
seems to enable, in at least some patients, recognition 
of anti-GBM disease early, when treatment is most 
Table 6. MS status of patients within the CDP.
Patient Date of 
alemtuzumab
Course 1
Date of 
alemtuzumab
Course 2
Date of 
alemtuzumab
Course 3 (if 
applicable)
Date of 
nephropathy 
eventa (months 
after final course)
EDSS score at 
study baseline 
(date)
EDSS score at 
most recent visit 
(date)
ARR from 
baseline to 
most recent 
visit
C June 2004 June 2005 September 2008 
(39)
0 (May 2004) 2.0 (June 2009) 0.2
D May 2008 May 2009 June 2010 October 2010 (4) 2.5 (May 2008) 1.5 (September 
2016)
0
E September 
2009
August 2010 January 2011 (5) 1.5 (August 2009) 3.5 (August 2016) 0.14
F February 
2010
March 2011 April 2012 (13) 3.5 (January 2010)b 6.0 (April 2016) 0.45
J July 2009 July 2010 August 2015 
(N/A)
3.0 (July 2009) 1.0 (May 2016) 0
CDP: clinical development program; EDSS: Expanded Disability Status Scale; ARR: annualized relapse rate; SC IFNB-1a: subcutaneous interferon beta-1a.
aDate when first symptoms were reported.
bBaseline EDSS score prior to receiving alemtuzumab in the CARE-MS extension study (patient F previously received SC IFNB-1a in CAMMS223).
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likely to preserve kidney function. Unfortunately, 
the earliest indication of the disease is microscopic 
hematuria, which has a low positive predictive value 
for anti-GBM disease, particularly in younger 
women who comprise the majority of the at-risk 
group.45 The Risk Management Plan/Risk Evaluation 
and Mitigation Strategy for alemtuzumab adopted 
for use in clinical practice, including monthly labo-
ratory monitoring required for 48 months following 
the last infusion, and healthcare professional and 
patient education on signs and symptoms of autoim-
mune events, may serve to mitigate against signifi-
cant renal damage.15,28
Conclusion
Autoimmune nephropathies occur at increased rates in 
MS patients treated with alemtuzumab. Close monitor-
ing can identify new cases early in the evolution of the 
nephropathy when treatment is most likely to be effec-
tive in preserving renal function. These findings are of 
critical importance, as the treatment of RRMS with 
alemtuzumab is expanding, having been judged to have 
a favorable benefit:risk profile in the majority of patients.
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